X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC LTD with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs GSK PHARMA - Comparison Results

ALEMBIC LTD    Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD GSK PHARMA ALEMBIC LTD/
GSK PHARMA
 
P/E (TTM) x 58.4 67.5 86.5% View Chart
P/BV x 2.4 13.6 17.9% View Chart
Dividend Yield % 0.4 2.1 19.7%  

Financials

 ALEMBIC LTD   GSK PHARMA
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
GSK PHARMA
Mar-18
ALEMBIC LTD/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs722,760 2.6%   
Low Rs342,040 1.7%   
Sales per share (Unadj.) Rs4.7339.0 1.4%  
Earnings per share (Unadj.) Rs6.141.4 14.7%  
Cash flow per share (Unadj.) Rs6.245.9 13.6%  
Dividends per share (Unadj.) Rs0.2035.00 0.6%  
Dividend yield (eoy) %0.41.5 25.9%  
Book value per share (Unadj.) Rs40.7242.9 16.7%  
Shares outstanding (eoy) m267.0384.70 315.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.37.1 159.1%   
Avg P/E ratio x8.757.9 15.0%  
P/CF ratio (eoy) x8.552.3 16.2%  
Price / Book Value ratio x1.39.9 13.2%  
Dividend payout %3.384.5 3.9%   
Avg Mkt Cap Rs m14,139203,280 7.0%   
No. of employees `000NANA-   
Total wages/salary Rs m2075,234 4.0%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m1,25528,715 4.4%  
Other income Rs m370545 67.9%   
Total revenues Rs m1,62529,260 5.6%   
Gross profit Rs m1115,059 2.2%  
Depreciation Rs m38380 9.9%   
Interest Rs m22 85.0%   
Profit before tax Rs m4425,222 8.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m0178 0.0%   
Tax Rs m241,892 1.3%   
Profit after tax Rs m1,6303,508 46.5%  
Gross profit margin %8.917.6 50.2%  
Effective tax rate %5.436.2 15.0%   
Net profit margin %129.812.2 1,062.9%  
BALANCE SHEET DATA
Current assets Rs m1,86721,815 8.6%   
Current liabilities Rs m59115,999 3.7%   
Net working cap to sales %101.620.3 501.8%  
Current ratio x3.21.4 231.6%  
Inventory Days Days9464 148.2%  
Debtors Days Days7419 393.6%  
Net fixed assets Rs m1,79112,475 14.4%   
Share capital Rs m534847 63.1%   
"Free" reserves Rs m10,32419,726 52.3%   
Net worth Rs m10,85820,573 52.8%   
Long term debt Rs m416 686.7%   
Total assets Rs m11,59139,475 29.4%  
Interest coverage x260.92,612.0 10.0%   
Debt to equity ratio x00 1,301.1%  
Sales to assets ratio x0.10.7 14.9%   
Return on assets %14.18.9 158.3%  
Return on equity %15.017.1 88.0%  
Return on capital %15.226.2 57.9%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m19564 3.4%   
Fx outflow Rs m2647,429 3.6%   
Net fx Rs m-244-6,865 3.6%   
CASH FLOW
From Operations Rs m2364,728 5.0%  
From Investments Rs m-224-1,042 21.5%  
From Financial Activity Rs m-27-3,066 0.9%  
Net Cashflow Rs m-15620 -2.4%  

Share Holding

Indian Promoters % 64.0 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 0.2 10.2 2.0%  
FIIs % 9.7 23.8 40.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 15.4 169.5%  
Shareholders   54,701 102,036 53.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   STRIDES SHASUN LTD  AJANTA PHARMA  UNICHEM LAB  ALEMBIC PHARMA  ELDER PHARMA  

Compare ALEMBIC LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY19); Net Profit Up 106.9% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, ALEMBIC LTD has posted a net profit of Rs 69 m (up 106.9% YoY). Sales on the other hand came in at Rs 445 m (up 50.4% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 235.3% (Quarterly Result Update)

Jul 26, 2018 | Updated on Jul 26, 2018

For the quarter ended June 2018, GSK PHARMA has posted a net profit of Rs 886 m (up 235.3% YoY). Sales on the other hand came in at Rs 7 bn (up 21.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Sep 19, 2018 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD 5-YR ANALYSIS

COMPARE ALEMBIC LTD WITH

MARKET STATS